Neupulse (the trading name for Neurotherapeutics Ltd.), a Nottingham, UK-based health tech company focused on patients with Tourettes Syndrome, raised $3.2M in Seed funding.
The round was led by Eos Advisory, alongside a consortium including US-based investors.
The company intends to use the funds to advance its wearable device aimed at tackling Tourettes Syndrome (TS) and other tic disorders towards commercialization.
Led by Paul Cable, CEO, Neupulse is developing a safe and effective non-drug treatment to reduce tics and the urge to tic. This is achieved through gentle stimulation of the median nerve in the wrist. It uses brain imaging and brain stimulation techniques to investigate the neural processes that give rise to tics, the brain correlates of premonitory urges and the mechanisms of brain plasticity that might lead to the control or reduction of tics.
Commenting on the news, Paul Cable said: “Tourettes Syndrome is a debilitating condition, severely so in many cases and to the detriment of quality of life, and our mission is to drastically reduce tics with an easy-to-use wearable device that will be transformative to the lives of affected individuals. Our device is an alternative to the current provision of treatment for TS, which is centred around medication and cognitive behaviour therapy. The goal is for Neupulse to be available to the TS community globally in the years ahead.”
Neurotherapeutics was founded as a spinout from the University of Nottingham in 2021.
FinSMEs
18/03/2024